慢性乙型肝炎阿德福韦酯疗效欠佳的影响因素分析及优化治疗疗效的探讨.PDF

()20115 5 2 ChinJExpClinInfectDis(ElectronicEdition), May20 11, Vol5, No.2 ·　　155 · ·· 李向永　林国莉　吴元凯　杨柳青　张秀娟　卢翠蓉　谢冬英　高志良　崇雨田 　　【 　　 (ADV), ADV。　ADV 3 48 HBVDNA≥10 /ml ADV。 147 ADV 。 ADV Logis- tic, ADV , HBVDNA, (Kaplan-Meier), Log-rank。 　Logistic, YMDD (OR:7.888, 95%C:I2.302 ～ 27.031, P=0.001 )、 HBeAg (OR:6.001, 95%C:I2.080 ～17.306, P= 0.001)、 HBVDNA (OR:1.635, 95%C:I1.007 ～2.655, P=0.047 )、 ADV (OR:15.214, 95%C:I1.800 ～128.609, P=0.0 12 )、 (OR:0.172, 95%C:I0.057 ～0.517, P=0.002 ) ADV 5 , YMDD、 HBeAg、 HBVDNA 、 ADV ADV 。 HBVDNA 。　YMDD、 HBeAg、 HBVDNA、 ADV ADV , 5 ADV。 【 　;,;; RelatedfactorsofchronichepatitisBpatientswithsuboptimalvirologicalre- sponsetoadefovirdipivoxilmonotherapyanddiscussionforoptimaltherapy　LI Xiang-yong, LINGuo-,liWUYuan-ka,iYANGLiu-qing, ZHANGXiu-juan, LUCui- rong, XIEDong-ying, GAOZhi-liang, CHONGYu-tian.DepartmentofInfectiousDis- ease,sTheThirdAffiliatedHospitalofSUNYat-SenUniversit,yGuangzhou510630, China Correspondingautho:rCHONGYu-tian, Emai:lytchong2005 @126.com 　　DO:I10.3 877/cma..jissn.1674 -1358.20 11.02.005 　　:“”(2009 ZX1000 1-018);(2007-ZDa-02 ) 　　:510 630　, 　　:, Emai:lytchong2005@126.com ·　　156 · ()2011 5 5 2 ChinJExpClinInfectDis(ElectronicEdition), May20 11, Vol5, No.2 【Abstract　Objective　ToidentifythehighriskfactorsofchronichepatitisBpa- tientswithsuboptmialvirologicalresponsetoadefovirdipivoxil(ADV)monotherap,y andanalyzetheefficacyofoptmialtherapy.Methods　Suboptmialvirologicalre- sponsetoADVmonotherapywasdefinedthattheserumHBVDNAlevelwasmorethan 1 logdeclineofviremiacomparedtobaselinebutstilldetectable(HBVDNA≥103 10 copies/ml)atthe48 thweek.All147 patientswhoreceivedADVmonotherapyforva- riousperiodswereanalyzed, retrospecetively.TheunivariateandmultivariateLogistic regressionmodelwereappliedforhighriskfactorsanalysis.Forpatientswiththese